stopping a glp-1 6 Ways to Safely Stop and Maintain Your Results In the original clinical trials

Ed Joins us to share helpful tips to keep you safe this summer.

The global incretin-based drugs market was valued at USD 39.4 billion in 2025 and is projected to grow from USD 41.6 billion in 2026 to USD 72.6 billion by 2035, expanding at a CAGR of 6.4% between 2026 and 2035, driven by the rising prevalence of type 2 diabetes mellitus.

Some people who take GLP-1 drugs such as semaglutide and tirzepatide see little to no changes to their weight

Our study focuses on Glucagon Like Peptide 1 Receptor (GLP1R) agonists that act beyond glycemic control in cardiovascular and metabolic health

Get a free case review now.

However, there may be unappreciated benefits of this combination of therapies